Search Results

Follica, Inc. announced that survey data on the unmet needs of AGA patients was accepted as a poster presentation at the 2022 Winter Clinical Dermatology Conference held in-person from January 14-19, 2022, in Koloa, Hawaii.

Follica Inc., a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial aging and other related conditions, announced the appointment of two veteran biotech executives to its Board of Directors.

PureTech Health plc is pleased to note that its Founded Entity, Follica, announced the appointment of two veteran biotech executives to its Board of Directors.

Follica, Inc., a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial aging and other related conditions, announced the publication of a pilot study evaluating scalp skin disruption to promote hair growth in female pattern hair loss in International Journal of Women’s Dermatology.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Follica, announced the publication of a pilot study evaluating scalp skin disruption to promote hair growth in female pattern hair loss in International Journal of Women’s Dermatology.

Follica’s platform is designed to induce an “embryonic window” in adult skin via a proprietary form of micro-abrasion that initiates hair follicle neogenesis, the formation of new hair follicles from epithelial stem cells.

Follica, Inc. announced positive feedback from a meeting with the U.S. Food and Drug Administration as the company prepares to advance its lead program into Phase 3 development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia announced in December 2019.

Demonstrated 44% improvement over baseline of visible (non-vellus) hair count, a well-established hair growth measure (p value < 0.001)

PureTech Health plc announces its results for the year ended December 31, 2023, as well as its cash balance as of the first quarter ended March 31, 2024.